Suppr超能文献

晚期胃肠道癌终末期姑息干预的应用。

Use of Palliative Interventions at End of Life for Advanced Gastrointestinal Cancer.

机构信息

Center for Innovations in Quality, Effectiveness, and Safety, Michael E DeBakey VA Medical Center, Houston, TX, USA.

Michael E. DeBakey VA Medical Center, Department of Surgery at Baylor College of Medicine, Houston, TX, USA.

出版信息

Ann Surg Oncol. 2022 Nov;29(12):7281-7292. doi: 10.1245/s10434-022-12342-1. Epub 2022 Aug 10.

Abstract

BACKGROUND

Despite the well-established benefits of palliative care, little is known about the use of palliative interventions among patients with advanced gastrointestinal (GI) cancer near the end of life (EOL).

METHODS

A national cohort study analyzed 142,304 patients with advanced GI cancers (stage 3 or 4) near EOL (death within 1 year of diagnosis) in the National Cancer Database (2004-2014) who received palliative interventions (defined as treatment to relieve symptoms: surgery, radiation, chemotherapy, and/or pain management). The study used multivariable hierarchical regression evaluate the association between the use of palliative interventions, temporal trends, and patient and hospital factors.

RESULTS

Overall, 16.5% of the patients were treated with a palliative intervention, and use increased over time (13.4% in 2004 vs 19.8% in 2014; trend test, p < 0.001). Palliative interventions were used most frequently for esophageal cancer (20.6%) and least frequently for gallbladder cancer (13.3%). Palliative interventions were associated with younger age (odds ratio [OR], 0.99; 95% confidence interval [CI], 0.98-0.99), recent diagnosis year (OR, 1.05; 95% CI, 1.04-1.06), black race (white [ref]; OR, 1.07; 95% CI, 1.01-1.12), insurance status (no insurance [ref]; private: OR, 0.92; 95% CI ,0.95-0.99), hospital type (community cancer program [ref]; integrated network cancer programs: OR, 1.37; 95% CI ,1.07-1.75), and stage 4 disease (OR, 2.17; 95% CI, 2.07-2.27). Patients in southern and western regions were less likely to receive palliative intervention (Northeast [ref]; OR, 0.76; 95% CI, 0.62-0.94 and OR 0.46; 95% CI, 0.37-0.57, respectively).

CONCLUSION

Increased palliative intervention use over time suggests ongoing changes in how care is delivered to GI cancer patients toward EOL. However, sociodemographic and geographic variation suggests opportunities to address barriers to optimal EOL care.

摘要

背景

尽管姑息治疗的益处已得到充分证实,但对于生命末期(EOL)晚期胃肠道(GI)癌症患者姑息干预的使用情况知之甚少。

方法

一项全国性队列研究分析了国家癌症数据库(2004-2014 年)中 142304 名 EOL(确诊后 1 年内死亡)的晚期 GI 癌症(3 或 4 期)患者的姑息干预措施(定义为缓解症状的治疗:手术、放疗、化疗和/或疼痛管理)。该研究使用多变量分层回归评估姑息干预措施的使用、时间趋势以及患者和医院因素之间的关联。

结果

总体而言,16.5%的患者接受了姑息治疗,且使用量随时间增加(2004 年为 13.4%,2014 年为 19.8%;趋势检验,p<0.001)。姑息治疗最常用于食管癌(20.6%),最不常用于胆囊癌(13.3%)。姑息治疗与年龄较小(比值比[OR],0.99;95%置信区间[CI],0.98-0.99)、最近诊断年份(OR,1.05;95%CI,1.04-1.06)、黑种人(白人[参照];OR,1.07;95%CI,1.01-1.12)、保险状况(无保险[参照];私人保险:OR,0.92;95%CI,0.95-0.99)、医院类型(社区癌症计划[参照];综合网络癌症计划:OR,1.37;95%CI,1.07-1.75)和 4 期疾病(OR,2.17;95%CI,2.07-2.27)相关。南部和西部地区的患者接受姑息治疗的可能性较低(东北地区[参照];OR,0.76;95%CI,0.62-0.94 和 OR,0.46;95%CI,0.37-0.57)。

结论

姑息治疗的使用随时间增加,表明在向 EOL 过渡过程中,GI 癌症患者的护理方式正在发生变化。然而,社会人口学和地理差异表明,有机会解决 EOL 护理的最佳障碍。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验